Shares of Trulieve Cannabis Corp. (OTCMKTS:TCNNF – Get Rating) have been given a consensus recommendation of “Buy” by the ten brokerages that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $48.94.
A number of research firms recently issued reports on TCNNF. Cowen reduced their target price on Trulieve Cannabis from $65.00 to $24.00 in a research note on Thursday, August 11th. Cantor Fitzgerald reduced their target price on Trulieve Cannabis from $57.00 to $54.00 and set an “overweight” rating on the stock in a research note on Thursday, August 11th. Craig Hallum reduced their target price on Trulieve Cannabis from $40.00 to $32.00 in a research note on Thursday, August 11th. Canaccord Genuity Group reduced their target price on Trulieve Cannabis from C$65.00 to C$57.00 and set a “buy” rating on the stock in a research note on Friday, August 12th. Finally, Stifel Nicolaus reduced their target price on Trulieve Cannabis from C$40.00 to C$36.50 in a research note on Thursday, August 11th.
Trulieve Cannabis Stock Performance
TCNNF opened at $8.66 on Friday. Trulieve Cannabis has a 1-year low of $8.29 and a 1-year high of $34.75. The stock’s 50 day simple moving average is $12.58 and its 200 day simple moving average is $14.46.
Trulieve Cannabis Company Profile
Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. It cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as through home delivery. The company produces flower, edible, vaporizer cartridge, concentrate, topical, capsule, tincture, dissolvable powder, and nasal spray products under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, and Roll One brands.
Featured Stories
Receive News & Ratings for Trulieve Cannabis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Trulieve Cannabis and related companies with MarketBeat.com’s FREE daily email newsletter.
Recent Comments